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EDITORIAL REVIEW
Apoptosis, nucleosomes, and nephritis in
systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune disease
that is characterized by the production of antinuclear autoanti-
bodies. The serological hallmark of SLE is the presence of
antibodies against double-stranded DNA. It is generally assumed
that these anti-DNA antibodies participate in the development of
lesions in this disease. The primary event inducing the formation
of anti-DNA antibodies has always been puzzling, since it has
been very difficult to demonstrate the presence of free DNA in
serum of SLE patients [1]. Furthermore, native DNA is usually
considered non-immunogenic [2, 31. In recent years, several
studies have been published which suggest that not DNA itself,
but DNA complexed to histones (nucleosomes) is the immuno-
genic particle involved both in the induction of pathogenic
anti-DNA antibodies, and in the pathophysiology of SLE.
In eukaryotic cells, DNA is packed in the nucleus in the form of
chromatin. In chromatin, adjacent nucleosomes are linked by
about 60 bp of DNA. Nucleosomes are the fundamental repeating
units of the chromatin string, and are responsible for the compac-
tion of DNA. Each nucleosome is built up by eight core histone
molecules (forming the histone octamer), one histone Hi mole-
cule and 146 bp of DNA [4], as shown in Figure 1.
Lately, it has become evident that at least in certain murine
models of SLE (lpr and gid mice), and perhaps also in SLE
patients as well, the process of apoptosis is aberrant. Apoptosis
(programmed cell death) results in fragmentation of the nucleus
by internucleosomal cleavage of the chromatin. Normally, these
apoptotic cells are phagocytosed rapidly, but if this does not occur
nucleosomes may be released. On the other hand, apoptosis of
maturing T cells is involved in establishing and maintaining
tolerance, and therefore a disturbed apoptosis may cause a
breakdown of tolerance. These recent data provide elements for a
new concept of SLE, both for the induction as well as for the
effector phase of the disease. We will first review the evidence for
disturbed apoptosis in SLE, and then discuss how this relates to
the immune response against nucleosomes. Subsequently, the
significance of nucleosomes for the disease manifestations of SLE
(with emphasis on glomerulonephritis) will be discussed.
Dysregulation of apoptosis in SLE
The term "apoptosis" was first used in 1972 to describe the
process in which cells undergo several morphological changes,
including condensation and fragmentation of the nucleus without
disruption of the plasma membrane [5]. It was later shown that
activation of an endogenous nuclease is involved in the internu-
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cleosomal cleavage of chromatin [6]. The induction of apoptosis is
under strict regulation by a variety of factors, including signals
from surrounding cells. With respect to T cells, for example, both
cytokines (such as interleukin-1, interleukin-2, interferon-y) and
costimulatory molecules (like ICAM-1, VCAM-1, LFA-3 and B7)
present on antigen-presenting cells determine whether a T cell is
driven to apoptosis or to cell proliferation [7—10]. Once a cell has
become apoptotic, it should be removed in a rapid and efficient
manner while still intact, to prevent the release of potentially toxic
cell contents. This removal of apoptotic cells occurs by phagocy-
tosis. Macrophages are the most important effector cell in this
respect, but other cell types like epithelial cells apparently can
also ingest neighboring cells undergoing apoptosis. Several differ-
ent receptors on the phagocyte surface may be involved in this
process, such as phosphatidylserine receptor and thrombospondin
receptors [ii]. The morphology of apoptotic cells in tissues and in
vitro has been described in detail [12, 13].
It has been very difficult to demonstrate the presence of free
DNA in serum from SLE patients, but when DNA was found it
occurred in the form of (oligo)nucleosomes [1]. A potential
source for these nucleosomes are apoptotic cells, since nucleo-
somes were spontaneously released from cultured normal murine
spleen cells, whereas this process did not occur when apoptosis
was blocked with zinc sulfate [14]. Also during culture of human
lymphocytes nucleosome release occurred, which was strongly
correlated with the degree of lymphocyte apoptosis [15]. It is,
however, not precisely known how nucleosomes are released from
apoptotic cells. It is conceivable that in some cases these nucleo-
somes derive from apoptotic bodies. These appear at the cell
surface of several cell types during apoptosis as a result of
packaging of cellular components as membrane-bounded blebs.
After their budding from the cell, apoptotic bodies are usually
rapidly ingested by phagocytes. Some of these apoptotic bodies
contain chromatin [13]. In a recent study on UV-injured kerati-
nocytes, it was demonstrated that some of the apoptotic bodies
contained nucleosomes, ribonucleoproteins (that are also targets
of autoantibodies in SLE), and in addition fragments of the
endoplasmatic reticulum or the nuclear membrane [16]. Nucleo-
somes may, after their release from apoptotic cells, also adhere to
specific "nucleosome receptors" present on the surface of viable
cells [17, 18]. In contrast to the programmed process of apoptosis,
cell death by necrosis is a more random process of cellular
destruction [12, 13] that is not expected to yield intact nucleoso-
mal particles.
In recent years it has become evident that, at least in certain
murine models, SLE is directly linked to a defect in apoptosis. We
will first discuss the data obtained in lupus-prone and transgenic
mice, and then address this question for human SLE. In mice, the
Ipr and gid genes provide single gene models of systemic autoim-
munity (including the formation of anti-dsDNA antibodies).
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Fig. 1. Diagram showing how the nucleosome is built up by eight histone
proteins (4 homodimers of H2A, H2B, H3, and H4) and two superhelical
turns of 146 bp of DNA. The N-terminal parts of the histone molecules
(approximately one third of the total molecule) contain positively charged
residues which are located on the outside of the nucleosome. Histone Hi,
which is located on the outside of the nucleosome, is not shown in this
diagram.
Although expression of the lpr gene in both B and T cells is
required for autoantibody production in lpr mice [19, 20], the
molecular basis of the lpr syndrome became only apparent when
Watanabe-Fukunaga et al [21] demonstrated that lpr mice lack the
expression of the Fas antigen. The Fas molecule (also known as
APO-1, and designated CD95) belongs to the TNF receptor
family, and is a cell-surface receptor that mediates apoptosis. The
aberrant transcription of the Fas gene in lpr mice is caused by the
insertion of a retroviral sequence in an intron [22—24]. Early
replacement of the lpr gene by the normal Fas gene will correct
the accelerated autoimmune disease in these mice [25]. These
findings demonstrate that in this model there is a causal relation-
ship between dysregulation of apoptosis and autoimmune disease.
The natural ligand for Fas has recently been cloned; it is a
transmembrane protein and a member of the TNF family [26].
The gid mouse strain has a mutation of the Fas ligand gene [27].
It therefore appears that either a defect in the receptor (lpr) or its
ligand (gid) causes systemic autoimmunity. How does the defect in
the Fas antigen cause autoimmunity in lpr mice? In view of the
important role of apoptosis in shaping the T cell repertoire by
negative selection, one is inclined to think that a defective Fas
antigen would cause aberrant thymic selection. It appears, how-
ever, that thymic selection of CD4+ or CD8+ T cells in these
mice proceeds normally [28]. In contrast, both subsets of mature
T cells exhibit decreased apoptosis in response to antigen stimu-
lation and therefore it has been suggested that autoimmunity in
this model results from a failure of peripheral tolerance [29, 30].
Also in gid mice, the T cell defect apparently is contained within
the compartment of activated, mature T cells rather than in the
thymus [31]. It seems probable that the defective Fas gene in lpr
mice may also cause a decreased antigen-induced apoptosis of
mature autoimmune B cells [21]. It is important, however, to
realize that even in lpr mice other genes are involved as well [32].
Since MRL/+ mice (which lack the lpr gene) also develop lupus
(although to a lesser extent, and later in life), it must be concluded
that lpr accelerates rather than causes the disease. In other murine
models of SLE, such as NZB/W mice, no abnormalities of the Fas
gene have been detected [22].
Apart from the Fas gene, there are several other genes involved
in the regulation of apoptosis. There are pathways for the
induction of apoptosis which are independent of the Fas antigen,
such as the TNF receptor [33]. Furthermore, there are genes that
decrease the susceptibility for apoptosis, such as the bcl-2 gene
[34]. The bcl-2 gene was first discovered in B cell lymphomas,
which have a permanent high expression of the bcl-2 protein.
When in transgenic mice bcl-2 was brought under the control of
an immunoglobulin promotor, the number of B cells increased,
and autoantibodies against nuclear antigens (including histone
and DNA) were produced, resulting in immune complex glomer-
ulonephritis [35]. In another study with transgenic mice, it could
be demonstrated that bcl-2 inhibits the clonal deletion of autore-
active B cells in the periphery but not in bone marrow [36]. In
bcl-2 knockout mice, fulminant lymphoid apoptosis was observed,
causing disappearance of the lymphoid system within four weeks
after birth [37, 38]. Recent studies have revealed that the bcl-2
gene is a member of an expanding family of similar genes, some of
which have the same effect as bcl-2 (protection against apoptosis),
whereas others like box will increase the susceptibility for apop-
tosis [39]. The bax protein can form a heterodimer with the bcl-2
protein and in this way neutralise the effect of bcl-2. The bcl-2
protein apparently exerts its protective effect by activating an
anti-oxidant pathway in the cell [40]. Many stimuli inducing
apoptosis are known to generate reactive oxygen species. The
relative amounts of bax and bcl-2 in a cell may therefore deter-
mine the susceptibility of the cell for apoptosis.
In human SLE, no defects in expression or function of the Fas
antigen have been found [41]. This does not imply, however, that
apoptosis is completely normal in human SLE. Two phenomena
have been described that may contribute to disturbed apoptosis in
human SLE. First, serum levels of soluble Fas were found to be
elevated in several SLE patients. Due to alternative splicing, the
Fas encoded protein can also occur in a soluble form. Soluble Fas
can inhibit apoptosis, since after injection in normal mice, it
causes increased numbers of B cells and autoimmune features
[42]. Secondly, in lymphocytes from SLE patients the expression
of bcl-2 is increased [43]. This may be a reflection of in vivo
activation, since lymphocyte activation is known to increase the
transcription of bcl-2 [44]. Despite these increases of soluble Fas
and intracellular bcl-2, lymphocytes from SLE patients display an
increased rate of "spontaneous" apoptosis in vitro [15], as do
lymphocytes from lpr mice [45]. One should be cautious, however,
to extrapolate from these in vitro findings to the in vivo situation.
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It has been postulated that lymphocytes from lpr mice may be
"primed" for apoptosis, but prevented from dying in vivo. Once
placed in culture in vitro, such cells would then rapidly die [45].
With respect to lymphocytes from SLE patients, the protective
effect of soluble Fas in serum will be diminished or absent when
cells are cultured in vitro. Furthermore, as mentioned above, the
rate of apoptosis of SLE lymphocytes in response to antigenic
stimulation is decreased [29, 30] instead of increased. It may be
important in this respect to precisely define the subset of lympho-
cytes that is being studied (double-negative T cells, or CD4-
positive T cells, or B cells), and their antigen specificity. It is
conceivable that some cells in SLE patients (or lupus-prone mice)
display an increased rate of apoptosis whereas for other cells
(depending on cell type, activation state, and specificity) apoptosis
may proceed at a decreased rate, or at the same rate as in normal
individuals. Therefore, although the Fas antigen is normal in
human SLE, apoptosis appears to be abnormal, as evidenced by
an increased concentration of soluble Fas, an increased expression
of bcl-2, and an increased rate of apoptosis when lymphocytes
from SLE patients are cultured in vitro. It remains to be proven
that the abnormalities of apoptosis observed in human SLE are a
cause of disease (as appears to be the case in the murine SLE
models discussed above) rather than a consequence.
Dysregulation of apoptosis can contribute to the pathogenesis
of lupus nephritis in two different ways. First, apoptosis appears to
be an important mechanism to induce tolerance of T cells towards
self-antigens [46, 47]. This implies that a disturbance in apoptosis
may cause persistence of autoreactive T cells and in this way affect
the magnitude of the anti-nucleosomal immune response. As
discussed above, one of the consequences of a defective Fas
antigen is breakdown of peripheral T cell tolerance. Secondly,
autoreactive lymphocytes that have escaped apoptosis in response
to autoantigen may be "primed" for apoptosis. Some of these cells
may be induced to become apoptotic by other mechanisms
(unrelated to Fas). Removal of such apoptotic lymphocytes may
be less effective (depending on the microenvironment) than when
apoptosis occurs by the "normal" (antigen-induced) mechanism.
In this respect it may be relevant that within tissues phagocytosis
of apoptotic bodies occurs rapidly, but not when they are formed
in a fluid medium [13]. A possibility that deserves further inves-
tigation is that in SLE patients phagocytosis of apoptotic cells
(and apoptotic bodies) might be decreased. Although there are no
published data yet on this subject, it has been known for a long
time that in SLE there are profound defects in other forms of
phagocytosis (such as complement-mediated phagocytosis in lu-
pus-prone mice [48], and Fe receptor-dependent phagocytosis in
SLE patients [49]). If phagocytosis of apoptotic cells is indeed
defective in SLE, this could also affect the persistence of non-
lymphoid apoptotic cells (such as UV-injured keratinocytes [16]).
Nucleosomes as immunogenic particles in SLE
In what way can dysregulation of apoptosis contribute to
autoimmunity against nucleosomal antigens in SLE? What is the
role of nucleosomes, and how are T lymphOcytes (double-nega-
tive, or CD4+ cells) and B cells involved in this process? As
discussed above, apoptosis is the most likely source of nucleo-
somes. Lymphocytes from SLE patients demonstrated an in-
creased rate of apoptosis in vitro, and the number of apoptotic
cells in freshly isolated lymphocytes was also slightly increased
[15]. If this reflects the in vivo situation, the increased number of
apoptotic lymphocytes might lead to the release of increased
amounts of nucleosomes. One way that nucleosomes can evoke an
immune response is by polyclonal activation of B cells. Both with
murine and human lymphocytes, polyclonal B cell activation by
nucleosomes has been demonstrated [14, 50]. The secretion of
interleukin-6 that was observed after interaction of nucleosomes
with murine spleen cells [18] may further enhance this polyclonal
B cell activation.
Although polyclonal B cell activation by nucleosomes may
occur, there are many arguments in favor of the hypothesis that
pathogenic anti-DNA antibodies are the result of an antigen-
driven immune response (such as clonal expansion, IgG class
switch, somatic mutations). T-helper (Th) cells are required for
the production of these anti-DNA autoantibodies. Since there is
an expanded population of double-negative T cells (CD3+,
CD4—, CD8—) in SLE [51, 52], and because these cells exhibit a
preferential use of distinct V13 genes both in lpr mice [511 and in
humans [53], these cells might be involved in the initiation of
autoimmune disease. Indeed, af3 CD4—CD8— (as well as y8
CD4—CD8—) T helper cell lines could be isolated from patients
with active lupus nephritis [52, 54]. The large majority, however,
of Th cells supplying help for production of pathogenic anti-DNA,
are CD4+ cells and not double-negative cells [541. Furthermore,
recent experiments with MHC class Il-deficient lpr mice have
demonstrated an important role for CD4+ Th cells, whereas
double-negative T cells did not appear to be essential for initiating
disease [551. It was found in lupus-prone mice that only a fraction
of autoreactive T cell clones can induce anti-DNA autoantibodies
in vitro, and accelerate the development of lupus nephritis when
transferred in vivo. The specificity of these pathogenic Th cells has
been studied in some detail. Approximately 50% of them were
specific for nucleosomal antigens. Importantly, nucleosome-spe-
cific CD4+ T cells were not detectable in normal mice, but they
were found in the spleens of lupus-prone mice as early as one
month of age, long before any autoimmune manifestation. These
nucleosome-specific Th cells not only augmented the anti-nucleo-
some response of syngeneic B cells, but also the anti-histone and
anti-DNA response. The importance of nucleosomes as immuno-
genic particles was underlined by the finding that injection of
purified nucleosomes into preautoimmune mice could signifi-
cantly accelerate the development of glomerulonephritis [56].
An intriguing question in this respect is the nature of the
epitope recognized by the pathogenic Th cell. These nucleosome-
specific Th clones were not activated by free DNA or histones, the
two components of nucleosomes. This result suggests that either
nucleosomes are taken up more efficiently by antigen-presenting
cells, or that critical Th cell epitopes in the histones are protected
from degradation by being bound to DNA [56]. Another possibil-
ity is that after antigen processing of nucleosomes, MHC class II
molecules present seif-peptides that were previously cryptic. The
possible significance of such cryptic epitopes for the induction of
autoimmunity has recently been reviewed [57]. It has also been
suggested that the presence of endoplasmatic reticulum or nu-
clear membrane within the apoptotic bodies causes an increased
generation of reactive oxygen species which may induce oxidative
modification of autoantigens. The unique peptide fragments
generated in this way could then, in genetically susceptible
individuals, be presented to Th cells and induce an autoimmune
response [16].
Whatever the precise nature of the epitope recognized by the
%
%
t 
a
 
'T
I—
 
Tax et al: Apoptosis, nucleosomes, and SLE nephritis 669
Fig. 2. Immunoelectron microscopy after perfusion of a monoclonal anti-
body complexed to nucleosomal antigens. Throughout the width of the
GBM, binding of the complexed antibody is seen (the noncomplexed, pure
antibody did not bind at all).
pathogenic Th cells, it is obvious that nucleosome-specific Th cells
were only present in lupus-prone and not in normal mice [56]. In
normal individuals, apoptosis also occurs but no anti-DNA anti-
bodies are found. Furthermore, injection of nucleosomes into
normal mice does not result in formation of anti-DNA autoanti-
bodies or nephritis [58]. It is apparent then that apart from the
extracellular presence of nuclear antigens, there must be other
factors involved in the induction of such autoreactive T cells. It is
well known that susceptibility to SLE is influenced by genes
encoded within the MHC complex [2, 55]. Furthermore, in lpr
mice the virtually absent expression of Fas may cause breakdown
of (peripheral) tolerance, as discussed above. This may result in
the prolonged survival in vivo of autoimmune T and B cells.
Anti-nucleosome antibodies
The occurrence of antibodies specific for nucleosomes or
subnucleosomal structures in SLE provides further evidence that
nucleosomes are immunogenic particles in SLE. These antibodies,
which only react with the intact nucleosome or subnucleosomal
structures, but not with its components DNA or individual
histones, have first been noted in drug induced lupus. In procain-
amide induced lupus not only antibodies to H2A-H2B complex
were found [59], but also to (H2A-H2B)DNA complexes [60].
Further analysis revealed that the antibodies recognize an epitope
created by the monomeric, trimolecular histone-DNA complex
[61]. Studies in lupus prone mice revealed that antibodies against
chromatin (such as nucleosomes) are the result of an antigen
driven response and precede the occurrence of anti-DNA or
anti-histone antibodies [62]. The authors concluded that anti-
DNA antibodies are a subset of the wide spectrum of anti-
chromatin (nucleosome) antibodies, which is also favored by the
observation that nucleosome specific T helper cells cannot only
induce an anti-nucleosome response, but also reactivity towards
DNA [56]. Recently, it was shown that the prevalence of anti-
nucleosome antibodies is very high (88%) in human lupus [63]
and that the titers of anti-nucleosome reactivity correlate with
disease severity [64]. One should realize, however, that the study
of these reactivities in polyclonal SLE sera is hampered by the fact
that anti-DNA and anti-histone antibodies will also bind to
nucleosomes. This problem is circumvented if one studies the
specificity of monoclonal antibodies derived from lupus prone
mice or SLE patients. Indeed, reactivity against histone/DNA
complexes has been found in such monoclonal antibodies (mAbs).
From MRL/Mp +1+ mice mAbs were obtained which exerted
reactivity against the (H2A-H2B)DNA complex [65], and recently
a murine mAb directed against the intact nucleosome, which did
not recognize any subnucleosomal structure, was described [66].
Also in mAbs derived from SLE patients reactivity against a
mixture of DNA and histones has been detected [67]. We recently
found that anti-nucleosome antibodies complexed to nucleosomal
material exerted anti-DNA reactivity both in ELISA and Farr
assay. After removal of the bound nucleosomal material the
anti-DNA reactivity disappeared and only anti-nucleosome reac-
tivity remained [68]. This indicates that in SLE sera reactivity
towards DNA can be a feature of anti-nucleosome antibodies. In
fact, we now have preliminary data that after purification of
anti-DNA positive SLE sera, a substantial part of the anti-DNA
reactivity is lost, whereas reactivity against other, nominal anti-
gens (for instance anti-EBV) is unaltered. This suggests that the
occurrence of anti-nucleosome antibodies in SLE might be more
prevalent than is assumed until now.
Relevance of nucleosomes for the pathophysiology of
SLE nephritis
Classically, not nucleosomes but DNA has been thought to play
a role in the development of tissue lesions in lupus through the
formation and subsequent deposition of DNA/anti-DNA im-
mune-complexes [69]. However, formal proof for this assumption
is rather lacking. It has been very difficult to detect circulating free
DNA or DNA complexed to anti-DNA antibodies [70—72]. Ru-
more and Steinman [1] showed that DNA in the circulation of
SLE patients was present in the form of (oligo)nucleosomes.
Based on these observations it is likely that DNA is not present in
naked form in the circulation but complexed in (oligo)nucleo-
somes. In addition, it is difficult to envisage how the anionic
charged DNA can have affinity for the anionic charged GBM.
The first notion, that nucleosomes might play a role in the
pathophysiology of glomerular disease in lupus, came from exper-
iments with cross reactive anti-DNA antibodies. Working with
anti-DNA mAbs which bound to heparan sulfate (HS) we found
that this cross reactivity was not exerted by the antibody itself, but
was mediated by nucleosomal material complexed to the antibody
[73]. HS is an intrinsic constituent of the GBM, and the negatively
charged side chain of heparan sulfate proteoglycan. It is respon-
sible for the negative charge of the GBM, and thus for the
charge-dependent permselectivity of the GBM [74]. Neutraliza-
tion of this HS associated charge, or antibody binding to HS leads
to albuminuria [75, 76]. We postulated that the positively charged
histones within the nucleosomal part of the immune complex
Fig. 3. Proposed mechanisms linking
dysregulation of apoptosis to lupus nephritis.
Nucleosomes can be released from
apoptotic cells (decreased phagocytosis
might be a contributing factor). Persisting
nucleosome-specific T cells can provide help
for production of anti-nucleosome
antibodies. Nucleosomes can mediate the
binding of such antibodies to anionic
structures in the GBM, such as heparan
sulfate (HS).
could interact with HS and that this interaction might lead to
albuminuria by neutralization of charge or by eliciting an inflam-
matory reaction [73]. At the same time Schmiedeke et al [77]
indeed showed that histone aggregates have a high affinity for the
GBM. We subsequently showed in a rat kidney perfusion system
that histones can mediate binding of subsequent perfused DNA
and anti-DNA and induce subepithelial or subendothelial local-
ization of the antibody depending on the perfusion protocol [78].
We propose that nucleosomes act as planted antigens or as
mediators for binding of autoantibodies to the GBM. Although
nucleosomes have a p1 of about 7, they contain many positively
charged N-terminal regions which are located on the outside of
the particle. It has even been shown that molecules with a net
negative charge, but with cationic regions can bind to the GBM
[79]. Indeed, we could show that nucleosome containing immune
complexes are able to bind to the GBM, whereas the purified
antibodies do not bind. Binding of such complexes to the GBM is
illustrated at the ultrastructural level in Figure 2. The pathogenic
potential of this binding was underlined by the fact that comple-
ment activation took place. Using heparinase perfusion prior to
perfusion of nucleosome containing immune complexes, we could
show that the ligand in the GBM was partly but not solely HS [68].
The exact composition of the nucleosomal material in the immune
complex which mediates the binding to the GBM in vivo is not
clear yet. In our studies we obtained immune complexes from
hybridoma culture supernatants and found that the four core
histones but not Hi were present, and DNA in the complexes
were predominantly the size of about 120 bp. The presence of
antibody bound to the nucleosome seems to be a critical deter-
minant, since we found that perfusion of naked nucleosomes did
not lead to a comparable binding to the GBM. Furthermore, the
specificity of the bound antibody could be important for the
overall p1 of the complex, for instance anti-DNA and anti-
nucleosome antibodies increase the p1 of the complex and thereby
the nephritogenicity. This concept is supported by the recent
finding that pathogenic anti-DNA antibodies, which are able to
bind to HS in the GBM via nucleosomes, harbor more charged
amino acids (like arginine) than non-pathogenic anti-DNA anti-
bodies [80]. In this concept binding of anti-histone antibodies, by
binding to the histone part of the nucleosome would both
decrease the p1 and the nephritogenicity of the complex. This
latter hypothesis is in line with the clinical observation that renal
disease is rare in SLE-like syndromes characterized by the occur-
rence of predominantly anti-histone antibodies as in drug induced
lupus.
What are the data to support the significance of nucleosomes in
vivo? Since HS reactivity is a feature of immune complexes
consisting of anti-nuclear autoantibodies and nucleosomal anti-
gens, anti-HS reactivity in plasma is an indirect way to identify the
presence of these immune complexes. Anti-HS reactivity has been
found to correlate with renal symptoms in lupus patients [81—83],
although anti-HS reactivity was not present in every episode with
renal manifestations [83]. Further evidence for the role of these
immune complexes comes from our observation that the staining
for glomerular HS in both human [84] and murine [85] lupus
nephritis is strongly reduced or even absent. Despite a nearly
complete loss of HS staining in mice with heavy and prolonged
albuminuria, glomerular HS content was unaltered. Therefore, we
had to conclude that HS was masked by immunoreactants pre-
sumably containing nucleosomal antigens. More direct evidence
for the involvement of nucleosomes in lupus nephritis is provided
by studies showing both histones [86, 87] and DNA [88] in
glomerular immune deposits in human and murine lupus nephri-
tis. In one study the deposition of histones was almost exclusively
found in albuminuric mice [87], underlining the role of histones
and nucleosomes in the development of albuminuria in these
mice. These in vivo data therefore support the concept that
nucleosomal material may mediate antibody binding to the GBM
for which HS is a ligand.
In conclusion, both in human and murine lupus abnormalities
in apoptosis have been described, This aberrant apoptosis may
contribute to lupus nephritis by mechanisms that have been
summarized in Figure 3. Binding of nucleosome containing com-
plexes to other basement membranes might lead to other organ
manifestations of the disease. However, many questions remain to
be answered. Future studies have to clarify the exact contribution
of disturbed apoptosis in SLE. In addition studies are needed to
identify the precise nature of the epitopes within the nucleosome
recognized by auto-reactive T cells. Furthermore, the possibility
should be studied that different epitopes within the nucleosome
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dictate the production of different autoantibodies (such as anti-
histone, anti-DNA, anti-nucleosome). Finally the exact composi-
tion of the nucleosome and the nucleosome/autoantibody com-
plex determining affinity for the GBM should be clarified.
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